anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prepare a cosmetic stable for a long period, and having excellent skin-beautifying effect such as prevention of fine wrinkles and aging of the skin, etc., and excellent cosmetic effects such as improved adhesivity and covering activity to the skin, improved feeling to the skin, etc., by compounding tri- or tetrapeptide to a cosmetic composition. CONSTITUTION:A cosmetic composition containing a tri- or tetrapeptide of formula (A is H, benzoyl, 1-adamantanecarbonyl or dancyl; pro is L-proline residue; B is residue of L-leucine, L-methionine, etc.; C is residue of glycine, sarcosine, etc.; D is residue of L-proline or phrrolidine; E is OH, lower alkoxy, amino, etc.). The composition has excellent skin-beautifying effects such as prevention of fine wrinkels and aging of the skin, etc., and excellent cosmetic effects such as improved adhesivity and covering properties to the skin, improved feeling to the skin, etc., high safety, and long-term stability. The amount of the peptide is 0.001-1wt% based on the cosmetic composition, and the peptide is compounded by dissolving in a solvent such as alcohol.
Arthralgex is a proprietary polyherbal preparation used in clinics to treat rheumatoid arthritis for decades. Its safety evaluation has not been reported. The study is aimed at evaluating the safety of arthralgex using Wistar rats, as per OECD guidelines. According to OECD 407, rats of either gender were separated into six groups (n= 6 each). The dose of arthralgex was decided based on an acute toxicity study. Under the treatment group, separate set of rats received arthralgex in three dose levels like - low, medium, and high (200, 400 & 800 mg/kg/day; p.o for 28 days). Satellite groups received high dose (800 mg/kg/day, p.o for 28 days), and control group received equal volume of vehicle. On day 28, blood samples were collected to estimate hematology and biochemistry parameters. Subsequently, rats were euthanized to collect organs for weighing and histopathology. Satellite groups were maintained for an additional 14 days post-treatment to assess toxicity reversibility and euthanized on day 43. Arthralgex did not show any signs of toxicity or major change in body weight in the acute toxicity study. Arthralgex has no significant adverse effect on general health status as confirmed by body weight, feed intake, hematology, biochemistry, urine analysis, internal organs, relative organ weight, and histopathological evaluation after 28 day treatment. Arthralgex could be considered safe for short-term treatment. Present findings may help researchers in dose fixing for sub-chronic and chronic toxicity studies, which is essential for safety evaluation for long-term use.
BACKGROUND AND OBJECTIVES: Lifestyle-related diseases (LSDs) impose a substantial economic burden on patients and health care services. LSDs are chronic in nature and can directly affect the heart and lungs. Therapeutic interventions only based on symptoms can be crucial for prompt treatment initiation in LSDs, as symptoms are the first information available to clinicians. So, this work aims to apply unsupervised machine learning (ML) techniques for developing models to predict drugs from symptoms for LSDs, with a specific focus on pulmonary and heart diseases.
METHODS: The drug-disease and disease-symptom associations of 143 LSDs, 1271 drugs, and 305 symptoms were used to compute direct associations between drugs and symptoms. ML models with four different algorithms - K-Means, Bisecting K-Means, Mean Shift, and Balanced Iterative Reducing and Clustering using Hierarchies (BIRCH) - were developed to cluster the drugs using symptoms as features. The optimal model was saved in a server for the development of a web application. A web application was developed to perform the prediction based on the optimal model.
RESULTS: The Bisecting K-means model showed the best performance with a silhouette coefficient of 0.647 and generated 138 drug clusters. The drugs within the optimal clusters showed good similarity based on i) gene ontology annotations of the gene targets, ii) chemical ontology annotations, and iii) maximum common substructure of the drugs. In the web application, the model also provides a confidence score for each predicted drug while predicting from a new set of input symptoms.
CONCLUSION: In summary, direct associations between drugs and symptoms were computed, and those were used to develop a symptom-based drug prediction tool for LSDs with unsupervised ML models. The ML-based prediction can provide a second opinion to clinicians to aid their decision-making for early treatment of LSD patients. The web application (URL - http://bicresources.jcbose.ac.in/ssaha4/sdldpred) can provide a simple interface for all end-users to perform the ML-based prediction.
NEW MATERIAL:Glycerin ether derivatives of formula I [R1 is formula II-V; R<2> is H, 1-26C straight or branched chain saturated or unsaturated hydrocarbon group or -CH2CH(OR)CH2OH]. EXAMPLE:1-O-abiethyl glycerin. USE:Useful as a component of an external preparation for skin. Having an effect for fundamental improvement of moisture retention properties of horny layer and capable of prevention and remedy of skin roughness. The above-mentioned effect is more improved by using a surfactant in combination. Used as a medically external preparation for skin and as cosmetics. PREPARATION:For example, an abiethyl alcohol of R<1>OH is reacted with epichlorohydrin in the presence of a base and the resultant product is reacted with acetone in the presence of a Lewis acid catalyst followed by hydrolysis in the presence of an acid catalyst, thus obtaining a compound of formula I.
This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via an organic linker molecule which is the targeted of a microorganism-specific protein having enzymatic activity. Thus, the invention provides cell targeting of drugs wherein the target drug is only released in cells infected with a particular microorganism. Alternative embodiments of such specific drug delivery compositions also contain polar lipid carrier molecules effective in achieving intracellular organelle targeting in infected phagocytic mammalian cells. Particular embodiments of such conjugates comprise antimicrobial drugs covalently linked both to a microparticle via an organic linker molecule and to a polar lipid compound, to facilitate targeting of such drugs to particular subcellular organelles within the cell. Also provided are porous microparticles impregnated with antimicrobial drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell. Methods of inhibiting, attenuating, arresting, combatting and overcoming microbial infection of phagocytic mammalian cells in vivo and in vitro are also provided.
Pediatric patients with type 1 diabetes (T1D) will have an eye exam using the Digital Retinography System (DRS) taking non-mydriatic fundus images. If the test is positive or inconclusive, subjects will be notified and referred to an ophthalmologist for a dilated retinal exam. A chart review and questionnaire will be completed to evaluate for risk factors predisposing subjects to diabetic retinopathy.
OBJECTIVES: Donor hepatectomy is a major surgery with a relatively safeprofile anda reportedcomplication rate of ~20%. Most complications are non-life threatening and are resolved with conservative measures. However, rare complications may need invasive precautions, ranging from percutaneous interventions to surgeries.
MATERIALS AND METHODS: We retrospectively analyzed all living donor hepatectomies at our center. Donors were divided into 2 groups: laparoscopic and open procedures. We collected preoperative, intraoperative and postoperative data of donors.Donor complications were recorded separately intraoperatively and postoperatively according to the Clavien-Dindo postoperative complication classification system.
RESULTS: Between July 2018 and April 2023, 215 living donors had hepatectomies, including 48 laparoscopic and 167 open donor hepatectomies. Among donors, 91 were female donors (42.3%) and 124 were male donors (57.7%).The meanage of alldonorswas 33.5±8.1 years, and the mean body mass index (in kilogram divided by meters squared) was 24.6 ± 3.8. Among donors, 124 underwent right and 91 underwent left or left lateral hepatectomies. The mean operative time for all donors was 301 ± 83 minutes, the mean hospital stay was 5.8 ± 1.4 days, and the mean follow-up was 31.9 ± 15.8 months. Four patients (1.8%) had intraoperative complications, including 2 cases of bleeding, 1 diaphragm perforation, and 1 portal vein stenosis. Fourteen patients (7.4%) had major postoperative complications, with 5 patients requiring surgical intervention.
CONCLUSIONS: Donor hepatectomy is a complicated surgery that requires extensive preoperative preparation and appropriate donor selection. Postoperative donor complications can be diagnosed early with close follow-up, and a multidisciplinary approach is essential for complication management.
A novel formulation for the prevention and treatment of COVID-19 is disclosed, featuring the antiviral properties of xylitol and bee propolis. These natural compounds were tested against porcine coronavirus (PEDV), human OC43 virus, and SARS-CoV-2. Notably, propolis and xylitol showed protective effects at concentrations below cytotoxic levels. The formulation is presented as a dental product with propolis (0.25-2.00 wt. %) and xylitol (0.25-3.0 wt. %) alongside various agents for oral and nasal applications. These findings suggest a promising approach to combat coronaviruses and provide an inventive solution for COVID-19 prevention and treatment.
This is a multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who have a maintained hematologic response to their most recent treatment for AL amyloidosis (e.g., chemotherapy, autologous stem cell transplant \[SCT\]) and have persistent renal dysfunction. Subject screening will occur during the 28 days prior to the first administration of study drug (i.e. month 1 day 1). If screening assessments are completed and all eligibility requirements are met, the subject will be enrolled. Study visits will occur every 28 days based on scheduling from month 1 day 1. A ±5-day window is allowed for visits starting after month 1. Subjects may receive up to 12 infusions of study drug. Subjects who discontinue study drug before the initial End of Study (EOS) visit should have an Early Treatment Discontinuation (ETD) Visit 30 (±5) days after their final administration of study drug. After completing 12 months of treatment and the confirmatory EOS visit, a subject may enter an open-label extension (OLE) study, during which subjects will receive active treatment with NEOD001 for 12 months and may receive concurrent chemotherapy.
Veliparib capsules (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
In the United States, inner-city African American and Latino youth are vulnerable to the negative consequences of sexual risk behavior. Despite the fact that sexual risk behavior is a dyadic behavior, almost all of the social-cognitive theories emphasize individual-based variables to explain behavior. Little research has studied both members of an adolescent couple or has used measures from each member to predict future sexual activity of that dyad. The overall aim of the present study is to identify explanatory models of couple sexual risk behavior among a sample of unmarried, non co-habiting Latino and African American high school-aged dyads that are romantically linked. In addition, the present research also will study the parents of adolescent couples. In doing so, the present research will apply theories of cognition, emotion and emotion regulation, and a new theory of parental monitoring to the study of adolescent sexual risk behavior among couples.
The present disclosure relates to a method of operating a chromatography column. The method involves collecting a column outlet signal and a cumulative flow parameter at two or more intervals of at least one flow phase transition front during operation of a chromatography column comprising a column packing. A model gamma cumulative distribution curve is determined based on the collected column outlet signals and the cumulative flow parameter of the at least one flow phase transition front. A theoretical plate equivalent Height (HETP) value of the at least one flowing phase transition front is calculated using parameters of the model gamma cumulative distribution curve, and the quality of the chromatography column packing is evaluated based on the calculated HETP value. If an adverse trend of HETP is observed during conventional column monitoring or control limits are exceeded, the elution product quality, column process performance, and/or impurity removal data should be evaluated to ensure product quality for the identified batch. If either of the product quality or the column performance fails to meet the standard settings, appropriate corrective actions should be performed, such as adjusting, recharging or replacing the column, and qualification, before release for further use.
Disclosed is a unique vehicle system which provides a desirable rheology to products formulated therewith, enhanced dispersion of actives therein, and improved deposition of actives therefrom. This vehicle system comprises a primary thickening agent which is a nonionic long-chain alkylated water-soluble polymer, and a secondary thickening agent which is a water-soluble surfactant, dispersed in a compatible solvent. Optionally, a rheological aid, which is a chelating agent may be included in the vehicle system. Also, optionally, a distributing aid, which is a water-soluble polymer of either high molecular weight or strong ionic character may be included in the vehicle system. These vehicle systems are useful in cosmetic compositions which are used to deliver an active component to the hair or skin. The vehicle systems are particularly useful in hair care compositions, especially rinse-off hair conditioning compositions, because they effectively deliver the hair conditioning component to the hair without depositing a substantial amount of the vehicle material onto the hair.
The research was conducted as a randomized controlled trial. The simple randomization method will be used for the assignment to groups. The data of the research; will be collected using the Preliminary Evaluation Form, Personal Information Form, Female Sexual Function Index, The International Consultation on Incontinence Questionnaire-ICIQ-SF (Turkish Version), and Fecal Incontinence Severity Index. The research will start at the 34th week of pregnancy and the questionnaires will be administered in the 3rd month after delivery. There will be 3 groups in the research.An active control group will be formed as the control group. The control group will be given the "Pelvic Floor Dysfunction Prevention Training" booklet prepared by the researchers. Experimental 1 group will receive perineal massage training in addition to the "Pelvic Floor Dysfunction Prevention Training" booklet given to the control group. Experimental 2 group will receive pelvic floor exercises in addition to perineal massage training and the "Pelvic Floor Dysfunction Prevention Training" booklet given to the control group.
ELLENCE is available in polypropylene single-dose CYTOSAFE™ vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use, clear, red solution in the following strengths:

Discard unused portion.

Store refrigerated between 2°C and 8°C (36°F and 46°F). Do not freeze. Protect from light.

Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours equilibration at controlled room temperature (15–25°C). Solution for injection should be used within 24 hours after removal from refrigeration.

ELLENCE is a cytotoxic drug. Follow applicable special handling and disposal procedures1 [see References (15)].
Caregivers in the standard of care-arm will receive immediate verbal feedback by a psychologist on their neurocognitive testing results, recommendations, and guidance for implementing recommendations (e.g., sending a 504 Plan request to the school). This report will contain information regarding background, test results, a summary and impressions, and bullet-pointed recommendations.
FIELD: medicine. SUBSTANCE: described are new substituted 4-biarylbutyric or 5-biarylpentanic acids or derivatives thereof of general formula: (T) x A-B-D-E-G wherein (T) x A,B,D,E,G are as defined in claim 1. Said compounds are capable of inhibiting matrix metalloprotease. Also described are method of preparation of said compounds, pharmaceutical composition based thereon and method of medical treatment. EFFECT: improved properties of the title compounds. 28 cl, 3 dwg, 429 ex
Patients receive venetoclax PO QD on days 1-28, nivolumab IV over 30 minutes on days 2 and 15 of cycles 1-4 and day 1 of each subsequent cycle, and rituximab IV on day 2 of cycle 1 and day 1 of cycles 2-6. Treatment repeats every 28 days up to 6 cycles in the absence of disease progression or unacceptable toxicity. After the completion of 6 cycles, rituximab is discontinued and patients receive venetoclax PO QD on days 1-28 and nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for up to 2 years total therapy in the absence of disease progression or unacceptable toxicity. Patients undergo tissue biopsy during screening. Patients undergo a bone marrow biopsy and blood sample collection as well as PET/CT and CT or MRI during screening and on the trial.
GOALS: We aim to explore the relationship between the use of proton pump inhibitors (PPIs) and upper gastrointestinal bleeding (UGIB). We develop a nomogram model to predict mortality in critically ill stroke patients.
STUDY: This is a retrospective study based on the MIMIC IV database. We extracted clinical information including demographic data, comorbidities, and laboratory indicators. Univariate and multivariable logistic regressions were used to assess and identify risk factors for the occurrence of UGIB and for the in-hospital mortality of critically ill stroke patients. The resulting model was used to construct a nomogram for predicting in-hospital mortality.
RESULTS: Five thousand seven hundred sixteen patients from the MIMIC-IV database were included in our analysis. UGIB occurred in 109 patients (1.9%), whereas the PPI use rate was as high as 60.6%. Chronic liver disease, sepsis, shock, anemia, and increased level of urea nitrogen were independent risk factors for the occurrence of UGIB in severe stroke patients. We identified age, heart failure, shock, coagulopathy, mechanical ventilation, continuous renal replacement therapy, antiplatelet drugs, anticoagulation, simplified acute physiology score-II, and Glasgow coma score as independent risk factors for in-hospital mortality in severe stroke patients. The C-index for the final nomograms was 0.852 (95% confidence interval: 0.840, 0.864).
CONCLUSIONS: We found that the overall rate of UGIB in severe stroke patients is low, whereas the rate of PPI usage is high. In our study, PPI was not identified as a risk factor for the occurrence of UGIB and UGIB was not associated with all-cause mortality. More clinical trials are needed to evaluate the benefits of using PPI in critically ill stroke patients.
To produce a medicament, especially an organic preparation from vegetable materials, a first substance containing a conventional medicament acts as an information emitter (20) for exposure to an electromagnetic field, giving the known therapeutic characteristics of the medicament within the framework of the receptor model based on the mol. condition of the medication. A physiologically acceptable aq. solution is used as an information receiver (21) for exposure to an electromagnetic field. The information emitter (20) and receiver (21) are separately and simultaneously exposed to both (i) a magnetic field in an appts. giving a static and homogenous field strength of 0.1 Tesla or more and (ii) a constant frequency electromagnetic HF field (4) which are applied together for at least 1 min. The field effect transfers the therapeutic information from the emitter (20) to the receiver (21) without contact between the two materials. The receiver (21) is the new medicament, with the transferred and stored information.
"Approval from Ethical Committee of Faculty of Medicine Universitas Indonesia was acquired prior conducting the study. Subjects were recruited using consecutive sampling method. Subjects underwent upper-abdominal surgery were screened. Eligible and consented subjects were randomized into intervention group (high-flow nasal cannula) and control group (conventional oxygen therapy). Subject and operation characteristics were recorded prior to intervention.

Clinical parameters (vital signs, Borg Score, ICON) were recorded in 10 specific times. diaphragm thickness data using abdominal ultrasonography (USG) and air lung distribution data using Electrical Impedance Tomography were collected in 7 specific times while lactate and blood gas analysis were done 4 times. "
The invention relates to an extraction process of a plant rumex gmelini and an extract thereof. The extraction steps are as follows: 1. The dried root of rumex gmelini is grinded into initial powder, and a certain weight amount of which is added into a Soxhlet extractor. 2. The initial powder in the Soxhlet extractor is constantly refluxed and extracted for 4h by 70ml of ethanol (50 percent) in the temperature of keeping the liquid boiling slightly. 3. The extract is filtered after cooling and is dried by distillation under normal pressure and at the temperature of 50 to 60 DEG C. 4. The acquired dry paste is crushed into powder by a conventional method, thus acquiring the rumex gmelini extract.